Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00125-012-2769-9 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Overview of diabetes agents in cardiovascular disease: it takes an orchestra to play Tchaikovsky in symphony.
Curr Opin Endocrinol Diabetes Obes
February 2025
Department of Endocrinology, Changi General Hospital.
Purpose Of Review: The aim of this review was to discuss the use and concerns of diabetes agents, clinical targets, and key aspects to be considered in the management of patients with type 2 diabetes mellitus (T2DM), and at high risk or established cardiovascular disease (CVD).
Recent Findings: The recent European and American guidelines recommended SGLT2 inhibitors and GLP-1 receptor agonists as the preferred first-line diabetes agents in patients with T2DM and CVD. This is a paradigm shift from using metformin as first-line therapy.
Therapeutic targets of antidiabetic drugs and kidney stones: A druggable mendelian randomization study and experimental study in rats.
Eur J Pharmacol
January 2025
Department of Urology, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, 410008, China; Department of Internal Medicine, Section Endocrinology, Yale University School of Medicine, New Haven, CT, 06519, USA. Electronic address:
Diabetes is known to increase the risk of kidney stones, but the influence of antidiabetic drugs on this risk remains uncertain. Genetic instruments for antidiabetic drugs were identified as variants, which were associated with both the expression of genes encoding target proteins of drugs and glycated hemoglobin level (HbA1c). Here, we investigated the effect of antidiabetic drugs on kidney stones in a mendelian randomization (MR) framework, and further explore the potential effect on CaOx stone rat models induced by glyoxylic acid.
View Article and Find Full Text PDFIntegrative analysis of toxicometabolomics and toxicoproteomics data: new molecular insights into thiazolidinedione-induced cardiotoxicity.
Metabolomics
December 2024
Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, 161 Cathedral Street, Glasgow, G4 0RE, UK.
Article Synopsis
- Thiazolidinediones (TZDs), like pioglitazone and rosiglitazone, are effective for treating type II diabetes but raise concerns about their role in heart failure risk, creating safety uncertainties that limit their use.
- This study employed a multi-omics approach to explore the mechanisms behind TZD-induced heart toxicity, revealing significant alterations in biochemical pathways related to energy metabolism and a shift towards anaerobic glycolysis in heart cells.
- Findings highlighted disruptions in the glutathione system and identified specific amino acid signatures linked to heart failure, suggesting these could be useful for early detection of TZD-related cardiotoxicity and potential therapeutic targets in the future.
Less frequent skin ulcers among patients with Werner syndrome treated with pioglitazone: findings from the Japanese Werner Syndrome Registry.
Aging (Albany NY)
December 2024
Department of Endocrinology, Hematology and Gerontology, Chiba University Graduate School of Medicine, Chiba, Japan.
Background And Aim: Werner syndrome (WS) is an autosomal recessive, adult-onset, progeroid syndrome caused by mutations. As refractory skin ulcers significantly affect the quality of life of patients with WS, this study identified ulcer risk factors and assessed prevention methods.
Methods: We analyzed the data of 51 patients with WS enrolled in the Japanese Werner Syndrome Registry between 2016 and 2022.
Objective Heart failure (HF) is an important underrecognized complication of type 2 diabetes mellitus (T2DM). Recent literature and recommendations support screening for HF among T2DM people attending the outpatient department (OPD) in non-emergency settings using a biomarker. The present study is a retrospective cross-sectional study that assesses the prevalence of screen positivity (S+) for undiagnosed HF among T2DM people (with normal electrocardiogram (ECG) and no history of heart disease) attending the OPD at a tertiary care center in India using N-terminal pro-B-type natriuretic peptide (NT-proBNP).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!